After a two-month search, Sanofi has its replacement for longtime CFO Jérôme Contamine, who is retiring at the end of September.
The drugmaker is bringing on Jean-Baptiste Chasseloup de Chatillon, formerly the CFO of French automaker PSA Group, for the role. During his career at PSA, Chasseloup de Chatillon served in varying management positions in Spain, the U.K. and Belgium, Sanofi said.
Chasseloup de Chatillon was part of the turnaround of the financially struggling auto company, which makes such brands as Peugeot, Citroën and Opel. That was accomplished, according to a BCG report, in part by selling 14% of PSA to a Chinese company and then simplifying manufacturing by significantly cutting the number of car models produced by PSA; to 26 by 2022, down from 45.
The new CEO will join the French drugmaker on Sept. 1 and start as CFO on Oct.1, working with Contamine during the month of September to get up to speed. Contamine will retire on Sept. 30.
Chasseloup de Chatillon joins Sanofi as the company continues to face competitive pressure in diabetes and as it works to respond. Last year, the drugmaker reported a U.S. diabetes sales decline of 22.8% due to CVS Health and UnitedHealthcare formulary exclusions for Lantus and Toujeo.
Well aware of its issues in diabetes, the drugmaker has been looking elsewhere for growth. It is already launching two new immunology drugs, Kevzara and Dupixent, and early this year inked two deals to expand its pipeline and rare disease presence. The company bought hemophilia-focused Bioverativ for $11.6 billion in January and followed that up days later with a $4.6 billion deal for nanobody biotech Ablynx.
During more than nine years at Sanofi, Contamine served under former CEO Chris Viehbacher and current CEO Olivier Brandicourt, helping both usher in their respective changes. After becoming CEO, Brandicourt reorganized the company into five global business units and has worked to refocus the drugmaker. Since splitting out the five units, Brandicourt offloaded animal health group Merial to Boehringer Ingelheim in exchange for BI’s consumer health organization.
In a statement, Brandicourt thanked Contamine for his service and said he has been a “highly committed and trusted business partner to me and to my executive team.”
Sanofi isn’t the only top drugmaker losing a CFO to retirement. Johnson & Johnson’s Dominic Caruso, the company’s longest-serving chief financial officer, decided he will retire in September. GlaxoSmithKline’s Simon Dingemans is also retiring next year.
By Eric Sagonowsky
Source: Fierce Pharma
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).